Twist Bioscience Corp

Key metrics

Financial performance

Over the last 8 fiscal years Twist Bioscience Corp's revenue grew from $10.77M to $376.57M, a compound annual growth rate of 55.9%. Net profit margin expanded from -550.8% to -20.6% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,494 filings)

Recent press releases

• Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference2026-05-27

  Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis , CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois .

• Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)2026-05-05

  As required by the rules of the Nasdaq Stock Market , Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist’s Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

• Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences2026-05-04

  Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products

• Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results2026-05-04

  Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations .

• Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 20262026-05-04

  Fiscal 2026 Second Quarter Financial Results Conference Call Details

Similar companies

The largest companies sharing Twist Bioscience Corp's SEC industry classification (biological products, (no diagnostic substances)).